ducovest

DRREDDY:NSE:NSE-Dr. Reddy's Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1262

Change

0.00 (0.00)%

Market Cap

USD 1,061.76B

Volume

0.54M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Company Website : https://www.drreddys.com

Currency: INR

Country : India

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

N/A

 USD 1,567.32B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

N/A

 USD 1,088.32B
MANKIND:NSE Mankind Pharma Ltd

N/A

 USD 1,013.86B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

N/A

 USD 1,007.64B
LUPIN:NSE Lupin Limited

N/A

 USD 997.68B
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

 USD 809.64B
ALKEM:NSE Alkem Laboratories Limited

N/A

 USD 687.74B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

N/A

 USD 478.44B
IPCALAB:NSE IPCA Laboratories Limited

N/A

 USD 403.32B
AJANTPHARM:NSE Ajanta Pharma Limited

N/A

 USD 386.34B

ETFs Containing DRREDDY:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -89.16% 4% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.16% 4% F 6% D-
Trailing 12 Months  
Capital Gain -88.24% 1% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.24% 1% F 5% F
Trailing 5 Years  
Capital Gain -77.59% 5% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.59% 5% F 8% B-
Average Annual (5 Year Horizon)  
Capital Gain 14.62% 22% F 23% F
Dividend Return 15.19% 23% F 23% F
Total Return 0.58% 59% D- 48% F
Risk Return Profile  
Volatility (Standard Deviation) 26.54% 90% A- 82% B
Risk Adjusted Return 57.23% 54% F 36% F
Market Capitalization 1,061.76B 97% N/A 96% N/A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.